Guardant Health says draft of LCD may expand Guardant360 Medicare coverage

On March 28, Guardant Health announced that Palmetto GBA, a Medicare Administrative Contractor, has posted a draft local coverage determination, LCD, that, if implemented, would expand Medicare coverage of the company’s Guardant360 assay from advanced non-small cell lung cancer, NSCLC, to over a dozen advanced solid tumor cancer types with guideline-recommended genomic targets.The draft LCD would apply to advanced cancer patients who are covered by Medicare for next-generation sequencing of tumor tissue, but have insufficient or unavailable tissue samples and are candidates for FDA-approved treatment that is recommended by the guidelines of the National Comprehensive Cancer Network as category 1 or 2A. These cases may comprise a significant percentage of advanced cancers, especially those that have spread to the deep viscera, bone, or brain. Palmetto GBA is expected to finalize and implement the draft LCD after soliciting public comments. There can be no assurances that Palmetto GBA will finalize and implement the draft LCD.
https://thefly.com/landingPageNews.php?id=2887033